|LETTER TO THE EDITOR
|Year : 2015 | Volume
| Issue : 9 | Page : 750
Could Crocus sativus (saffron) be combined with conventional therapies for ocular diseases?
Prasan R Bhandari
Department of Pharmacology, SDM College of Medical Sciences and Hospital, Dharwad, Karnataka, India
|Date of Web Publication||3-Dec-2015|
Dr. Prasan R Bhandari
Department of Pharmacology, SDM College of Medical Sciences and Hospital, Sattur, Dharwad - 580 009, Karnataka
Source of Support: None, Conflict of Interest: None
|How to cite this article:|
Bhandari PR. Could Crocus sativus (saffron) be combined with conventional therapies for ocular diseases?. Indian J Ophthalmol 2015;63:750
|How to cite this URL:|
Bhandari PR. Could Crocus sativus (saffron) be combined with conventional therapies for ocular diseases?. Indian J Ophthalmol [serial online] 2015 [cited 2020 May 31];63:750. Available from: http://www.ijo.in/text.asp?2015/63/9/750/170978
Oxidative stress due the continuous contact of ocular tissues with radiation, atmospheric oxygen, environmental chemicals, and physical abrasion has been proposed to play a vital role in diseases such as glaucoma, cataract, uveitis, retrolental fibroplasias, age-related macular degeneration (AMD), and various forms of retinopathy. This offers a prospect for novel approach to their prevention and treatment. Unfortunately, there are no curative treatment options for AMD, and even palliative treatments are few. The utilized therapeutic modalities are associated with various adverse effects, are costly, and only manage the consequence without tackling the cause of the pathology. Hence, many novel options are being investigated. Conventional and newly promising management measures have not accomplished in reversing the outcome of ocular diseases to any radical extent. This has implied researchers to investigate alternative treatment options. Hence, the widespread collections of traditional medicinal knowledge systems from various parts of the world are re-investigated for their healing properties.
Crocus sativus L., commonly known as saffron, is the raw material for one of the most expensive spices in the world, and it has been used in folk medicine for centuries. The major active constituents of saffron are crocin, crocetin, and safranal. There is increasing substantiation that the spice saffron, which contains powerful anti-oxidants, offers protection against neurodegenerative disorders, including AMD and Alzheimer’s disease.
Ischemic retinopathy and AMD are the foremost ocular diseases that cause blindness. The etiology of these diseases is due in part to the reduction of blood flow in the retina and/or choroid. Crocin analogs isolated from C. sativus L. were found to significantly increase the blood flow in the retina and choroid and to facilitate retinal function recovery. Experimental studies conducted by Ishizuka et al. have demonstrated that crocetin prevents ischemia-induced retinal damage through its inhibition of oxidative stress. Results from the experiment by Yamauchi et al. suggest that crocetin has protective effects against retinal damage in vitro and in vivo, indicating that crocetin could suppress increase in caspase-3 and caspase-9 activities following retinal damage. In a randomized clinical trial, it was demonstrated that short-term saffron supplementation improves retinal flicker sensitivity in early AMD.
Saffron extract prevented selenite-induced cataract formation in Wistar rats, probably due to the fortification of antioxidant status, diminution of the concentration of lipid peroxidation, shielding the sulfhydryl groups, and suppression of proteolysis of the lens water-soluble fraction. These findings highlight the anticataractogenic potential of saffron by virtue of its antioxidant property.
These attractive effects propose its presence as a therapeutic agent in future. Though saffron and its constituents have shown multiple useful effects, clinical evidence is still scarce in this regard, and more comprehensive studies with special focus on human clinical trials are required.
Financial support and sponsorship
Conflicts of interest
There are no conflicts of interest.
| References|| |
Purushothuman S, Nandasena C, Peoples CL, El Massri N, Johnstone DM, Mitrofanis J, et al
. Saffron pre-treatment offers neuroprotection to Nigral and retinal dopaminergic cells of MPTP-treated mice. J Parkinsons Dis 2013;3:77-83.
Xuan B, Zhou YH, Li N, Min ZD, Chiou GC. Effects of crocin analogs on ocular blood flow and retinal function. J Ocul Pharmacol Ther 1999;15:143-52.
Ishizuka F, Shimazawa M, Umigai N, Ogishima H, Nakamura S, Tsuruma K, et al
. Crocetin, a carotenoid derivative, inhibits retinal ischemic damage in mice. Eur J Pharmacol 2013;703:1-10.
Yamauchi M, Tsuruma K, Imai S, Nakanishi T, Umigai N, Shimazawa M, et al
. Crocetin prevents retinal degeneration induced by oxidative and endoplasmic reticulum stresses via inhibition of caspase activity. Eur J Pharmacol 2011;650:110-9.
Falsini B, Piccardi M, Minnella A, Savastano C, Capoluongo E, Fadda A, et al
. Influence of saffron supplementation on retinal flicker sensitivity in early age-related macular degeneration. Invest Ophthalmol Vis Sci 2010;51:6118-24.
Makri OE, Ferlemi AV, Lamari FN, Georgakopoulos CD. Saffron administration prevents selenite-induced cataractogenesis. Mol Vis 2013;19:1188-97.